论文部分内容阅读
目的:评价多西他赛联合顺铂治疗晚期非小细胞肺癌(NSCLC)的疗效和不良反应。方法:选择不能手术的Ⅲ期B-Ⅳ期非小细胞肺癌36例,应用多西他赛加顺铂化疗。结果:总有效率44.4%,不良反应为骨髓抑制,胃肠道反应等,均可耐受。结论:多西他赛联合顺铂治疗晚期NSCLC有效安全,值得临床推广应用。
Objective: To evaluate the efficacy and adverse effects of docetaxel plus cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: Thirty-six patients with stage Ⅲ-B-Ⅳ non-small cell lung cancer who were inoperable were treated with docetaxel plus cisplatin. Results: The total effective rate was 44.4%. Adverse reactions were myelosuppression, gastrointestinal reactions and so on. Conclusion: Docetaxel plus cisplatin is effective and safe in the treatment of advanced NSCLC, which is worthy of clinical application.